Table 5 Effect-modification of the amikacin or kanamycin exposure and the occurrence of hearing loss in MDR-TB treatment
Variable | Strata | Stratum-specific crude OR (95Â % Confidence Interval) | P-value (Breslow-Day test of homogeneity across strata) |
|---|---|---|---|
Age | Age 0–24 years | 2.0 (0.4–10.6) |  |
|  | Age 25–34 years | 2.8 (0.8–9.2) | 0.99 |
|  | Age 35–44 years | 2.6 (0.8–8.2) |  |
|  | Age 45+ years | 3.0 (0.4–26.4) |  |
Baseline body weight | Weight 18–39 kgs | NA |  |
|  | Weight 40–59 kgs | 2.8 (1.1–6.8) | 0.06 |
|  | Weight 60+ kgs | 1.1 (0.4–3.0) |  |
Sex | Female | 1.1 (0.4–3.0) | 0.06 |
|  | Male | 4.5 (1.5–13.4) |  |
HIV status | HIV negative | 1.7 (0.7–4.1) |  |
|  | HIV positive | 3.4 (1.1–10.6) | 0.33 |